Itching and inflammation dominate most dermatoses and adversely affect the quality of life of patients. To manage these conditions, active therapy is needed, which should be effective and safe. Objective — to compare the terms of resolution of clinical manifestations of itchy dermatosis using combination therapy (Neotanin+topical glucocorticoid) and monotherapy with topical glucocorticoid. Material and methods. This open label comparative clinical trial was conducted from October 2018 to April 2019. The study included 40 patients of both sexes aged 7—43 with acute itchy dermatosis, with and without wetness, including those complicated by secondary infection, with comparable lesions on the mirror parts of the body. The efficacy criteria of the study drug were the dynamics of subjective complaints, objective assessment of the patient’s condition (presence and severity of clinical symptoms), dynamics of the dermatological index of quality of life (DIKG). Results. The use of combination therapy (Neotanin+topical glucocorticoid) significantly reduces the intensity of itching: by the 3rd day of the study it decreased by 60%, in case of monotherapy with topical glucocorticoid — only by 22% (p=0.02). When Neotanin was added to the therapy, itching stopped much faster than (after 8-15 minutes) compared with topical glucocorticoid monotherapy (average after 60 minutes), p<0.01. The duration of antipruritic action after Neotanin applying averaged 2—3 hours, with monotherapy 30 minutes, p<0.01Thus, the duration of antipruritic action in combination therapy is 4 times higher than in monotherapy. Conclusion. The use of complex therapy in patients with exacerbation of itching dermatoses allowed to significantly reduce the intensity and duration of itching, reduce the steroid load on the skin and significantly improve the quality of life of patients.